independence blue cross glp 1 GLP-1 Drugs Could Raise Employer Health Premiums Excellus BCBS will stop paying
Description
10.3389/fimmu.2018.01920 111 WrobelL
M., LaSalle, J
Cochrane, A
This genetic-guided approach personalizes treatment selection more rigorously than trial-and-error polypharmacy
Baocheng Xie, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion
